SRS Capital Advisors Inc. Buys 274 Shares of IQVIA Holdings Inc. (NYSE:IQV)

SRS Capital Advisors Inc. grew its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 158.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 447 shares of the medical research company’s stock after buying an additional 274 shares during the quarter. SRS Capital Advisors Inc.’s holdings in IQVIA were worth $88,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Maia Wealth LLC grew its holdings in shares of IQVIA by 14.7% in the 4th quarter. Maia Wealth LLC now owns 14,639 shares of the medical research company’s stock valued at $3,030,000 after buying an additional 1,872 shares during the period. Cantillon Capital Management LLC increased its stake in shares of IQVIA by 12.3% during the 4th quarter. Cantillon Capital Management LLC now owns 2,066,144 shares of the medical research company’s stock worth $406,018,000 after purchasing an additional 226,017 shares during the last quarter. Middleton & Co. Inc. MA lifted its position in shares of IQVIA by 1.3% in the fourth quarter. Middleton & Co. Inc. MA now owns 48,438 shares of the medical research company’s stock valued at $9,519,000 after buying an additional 601 shares during the last quarter. Nichols & Pratt Advisers LLP MA boosted its position in IQVIA by 2.7% during the fourth quarter. Nichols & Pratt Advisers LLP MA now owns 109,144 shares of the medical research company’s stock worth $21,448,000 after purchasing an additional 2,899 shares during the period. Finally, Metis Global Partners LLC increased its stake in shares of IQVIA by 19.5% during the fourth quarter. Metis Global Partners LLC now owns 10,023 shares of the medical research company’s stock worth $1,970,000 after purchasing an additional 1,633 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on IQV. UBS Group lowered their price objective on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Truist Financial reaffirmed a “buy” rating and issued a $263.00 price objective (up from $261.00) on shares of IQVIA in a research note on Monday, February 10th. JPMorgan Chase & Co. cut their target price on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 18th. Barclays decreased their target price on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd. Finally, BTIG Research lowered shares of IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Stock Down 0.2 %

Shares of IQV stock opened at $185.45 on Friday. IQVIA Holdings Inc. has a 1-year low of $179.28 and a 1-year high of $261.73. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company has a market cap of $32.70 billion, a price-to-earnings ratio of 24.73, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The stock’s fifty day moving average price is $197.95 and its 200 day moving average price is $213.47.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.